Consider POAML in Progressive Eyelid Swelling, Even in Young Women
Eyelid Swelling in a Young Woman Turns Out to Be Rare Lymphoma
This case report and literature review describes a 35-year-old woman with primary ocular adnexal MALT lymphoma (POAML) of the right upper ey…
A 35-year-old woman's stubborn eyelid swelling was a rare lymphoma. Surgery and radiation put it into remission.
CSF IL-6 and MCP-1 levels distinguish neuropsychiatric involvement in systemic lupus erythematosus patients
Blood and fluid markers help identify lupus brain involvement
This meta-analysis of 93 studies evaluated blood and cerebrospinal fluid analytes to identify biomarkers for neuropsychiatric involvement in…
New research identifies specific markers in blood and spinal fluid that help distinguish lupus patients with brain involvement from those wi…
Sickle cell trait is associated with increased risk of kidney disease, pulmonary embolism, and anemia
Sickle cell trait linked to higher risks of kidney and blood issues
This meta-analysis analyzed 4,813 individuals with sickle cell trait (SCT) to identify phenome-wide and laboratory-wide associations. The st…
New data shows that people with sickle cell trait may face higher risks for kidney disease, anemia, and other serious health conditions.
Evaluating Cytokine and Molecular Biomarkers for Diagnosing Primary Vitreoretinal Lymphoma
Biomarkers Show Promise in Detecting Vitreoretinal Lymphoma
A meta-analysis identifies the IL-10 to IL-6 ratio and MYD88 as high-performing biomarkers for distinguishing vitreoretinal lymphoma from in…
New research identifies specific biomarkers that may help doctors more accurately detect and diagnose a rare type of eye cancer.
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL
Trial shows blinatumomab improves survival for pediatric B-cell leukemia
This meta-analysis of randomized trials found that adding blinatumomab to chemotherapy improved disease-free survival (RR 0.63) and overall …
Adding blinatumomab to chemotherapy may improve survival rates for children with specific types of high-risk or relapsed B-cell leukemia.
RBC alloimmunization affects 8.76% of transfused sickle cell patients in resource-limited settings
New data shows common risks for sickle cell disease patients
This meta-analysis pooled data from 3128 patients with sickle cell disease who received red blood cell transfusions in resource-limited coun…
New data reveals that nearly 9% of sickle cell patients who receive blood transfusions develop a common immune reaction.
Mesenchymal stromal cells and MSC-derived extracellular vesicles may reprogram neuroimmune responses in neurodegenerative diseases
Stem cells and vesicles show potential for neurodegenerative diseases
This critical review examines the mechanisms and translational barriers of mesenchymal stromal cells (MSCs) and MSC-derived extracellular ve…
New research explores how stem cell products might protect the brain and repair blood-brain barriers in diseases like Parkinson's and Alzhei…
Mechanistic-driven diagnosis and therapy shift focus from platelet counts to underlying pathophysiology of thrombocytopenia
New Framework Offers Precise Treatment for Low Blood Platelets
This systematic review synthesizes the multidimensional pathogenesis of thrombocytopenia across five axes including production, immune-media…
A new diagnostic framework moves beyond simple blood counts to identify the specific cause of low platelets for more precise treatment.
FDA Approves Gazyva (obinutuzumab) for Chronic Lymphocytic Leukemia
FDA Approves New Drug Combo for Untreated Chronic Lymphocytic Leukemia
The FDA has approved Gazyva (obinutuzumab) in combination with chlorambucil for the treatment of patients with previously untreated chronic …
The FDA has approved Gazyva (obinutuzumab) to be used with chlorambucil for adults with previously untreated chronic lymphocytic leukemia (C…
FDA Approves Scemblix (asciminib) for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
FDA Approves New Daily Pill for a Common Type of Adult Leukemia
The FDA granted accelerated approval to Scemblix (asciminib) for adult patients with newly diagnosed Philadelphia chromosome-positive chroni…
The FDA approved a new drug called Scemblix for adults with chronic myeloid leukemia, a blood cancer. It can be used for people newly diagno…
Specific biomarkers like CD4/CD8 ratio inversion and T-cell senescence markers indicate immune aging in HIV
New markers help track immune aging in people living with HIV
This systematic review evaluates candidate biomarkers of immune aging in adults living with HIV undergoing long-term antiretroviral therapy …
New markers like T-cell senescence and cytokine panels help doctors track how immune aging affects people living with HIV on long-term treat…